Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $59

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $58 to $59.